Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRelapseMMStudy
2024-510590-14-00Phase 3Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Sep 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of allogeneic hematopoietic stem cell transplantation in multiple myeloma (MM) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Overall survival at 5 years after randomization. Started Sep 2024; status: completed.
02
Drugs
allogeneic hematopoietic stem cell transplantation
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-510590-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510590-14-00.